Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors

Laurel W. Rice, Rebecca L. Stone, Miaohou Xu, Mary Galgano, Mark H. Stoler, Elise N. Everett, Amir A. Jazaeri

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The purpose of this study was to investigate the AKT signaling cascade in endometrial cancers and to assess its therapeutic potential. Study design: Western blotting and immunohistochemistry were used to investigate the expression of estrogen receptor, progesterone receptor, HER2, AKT, and 4EBP1 proteins in 27 atrophic endometria, 31 grade 1 and 24 grade 3 endometrioid endometrial cancers, and 19 malignant mixed müllerian tumors. Inhibition of the AKT signaling cascade was investigated in cell lines. Results: Malignant mixed müllerian tumors and grade 3 endometrioid endometrial cancers demonstrated higher levels of AKT and 4EBP1 activation and hormone receptor loss compared with grade 1 endometrioid endometrial cancers and atrophic samples. HER2 over-expression was identified most often in grade 3 tumors without gene amplification. In endometrial cancer cell-lines, AKT cascade inhibitors decreased cell proliferation by apoptosis and cell cycle arrest. Conclusion: AKT cascade activation in grade 3 endometrioid endometrial cancers and malignant mixed müllerian tumors is a novel finding. Apoptosis and growth arrest that results from AKT inhibition expose opportunities for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)1119-1126
Number of pages8
JournalAmerican journal of obstetrics and gynecology
Volume194
Issue number4
DOIs
StatePublished - Apr 1 2006
Externally publishedYes

Keywords

  • AKT
  • Endometrial cancer
  • Malignant mixed müllerian tumor
  • mTOR

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors'. Together they form a unique fingerprint.

Cite this